Biogen Idec Earnings: Here’s Why Investors are Bidding Up Shares

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Biogen Idec Inc. (NASDAQ:BIIB) delivered a profit and missed Wall Street’s expectations, BUT beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 1.1%.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Biogen Idec Inc. Earnings Cheat Sheet

Results: Net income decreased -2.71% to $292.1 million ($1.4 per diluted share) in the quarter versus a net gain of $300.24 million in the year-earlier quarter.

Revenue: Rose 7.03% to $1.42 billion from the year-earlier quarter.

Actual vs. Wall St. Expectations: Biogen Idec Inc. reported adjusted net income of $1.4 per share. By that measure, the company missed the mean analyst estimate of $1.46. It beat the average revenue estimate of $1.39 billion.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business